Ocuphire Pharma Investor Day Presentation Deck
RM
73
Summary of Nyxol Reversal of Mydriasis Program
Nyxol, the first ophthalmic formulation of phentolamine mesylate, is a differentiated MOA
uniquely suited for reversal of pharmacologically-induced mydriasis
c
In MIRA-1 and MIRA-2, Nyxol met its primary endpoint of rapidly returning subjects as
well as many key secondary endpoints
Consistent with prior trials, Nyxol has demonstrated favorable safety and tolerability with a
MOA uniquely suited to avoid safety issues associated with cholinergic drug (e.g.
pilocarpine) reversal of dilations
MIRA-3 Phase 3 and MIRA-4 Pediatric Safety trials are currently enrolling patients at 15
sites in the US with data expected in early 2022
We anticipate the results of these trials will support an NDA submission for Nyxol in late
2022
Nyxol has the potential to be the ONLY commercially-available, FDA-approved Rx
treatment to reverse pupil dilation in a growing $500+M US Market
Ocuphire
PHARMAView entire presentation